Fluoxetine blocks myotonic runs and reverts abnormal surface electromyogram pattern in patients with myotonic dystrophy type 1

Clinical Neuropharmacology

Volumn 32, Issue 6, 2009, Pages 330-334

  Chisari, Carmelo ^a   Licitra, Rosaria ^a   Pellegrini, Monica ^a   Pellegrino, Mario ^a   Rossi, Bruno ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

EMG; Fluoxetine; Myotonia; Myotonic dystrophy

Indexed keywords

FLUOXETINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; ELECTRIC ACTIVITY; ELECTROMYOGRAPHY; FEMALE; HUMAN; MALE; MUSCLE EXCITATION; MYOTONIA; MYOTONIC DYSTROPHY; PRIORITY JOURNAL; TIBIALIS ANTERIOR MUSCLE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ELECTROMYOGRAPHY; FEMALE; FLUOXETINE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MUSCLE, SKELETAL; MYOTONIA; MYOTONIC DYSTROPHY; RECOVERY OF FUNCTION; TREATMENT OUTCOME;

EID: 74249098227     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181ae5546     Document Type: Article

References (35)

1. Harper PS. Myotonic Dystrophy. London: WB Saunders Co. Ltd.; 2001.
2. Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3-end of a transcript encoding a protein kinase family member. Cell 1992;68:799-808.
3. Fu YH, Pizzuti A, Fenwich Jr RG, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992;255: 1256-1258.
4. Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3-untranslated region of the gene. Science 1992;255:1253-1255.
5. Aslanidis C, Jansen G, Amemiya C, et al. Cloning of the essential myotonic dystrophy region and mapping of the putative defect. Nature 1992;355:548-551.
6. Tapscott SJ, Thornton CA. Reconstructing myotonic dystrophy. Science 2001;293:816-817.
7. Cho DH, Tapscott SJ. Myotonic dystrophy: emerging mechanisms for DM and DM2. Biochim Biophys Acta 2007;1772:195-204, 2007.
8. Wheeler TM, Thornton CA. Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol 2007;20:572-576.
9. Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 2005;32: 1-18.
10. Rudel R, Lehmann-Horn F. Membrane changes in cells from myotonia patients. Physiol Rev 1985;65(2):310-356.
11. Gruener R, Stern LZ, Markovitz D, et al. Electrophysiologic properties of intercostals muscle fibers in human neuromuscular disease. Muscle Nerve 1979;2:165-172.
12. Edstrom L, Wroblewski R. Intracellular elemental composition of single muscle fibers in muscular dystrophy and dystrophia myotonica. Acta Neurol Scand 1989;80:419-424.
13. Franke CH, Hatt H, Iaizzo PA, et al. Characteristics of Na+ channels and ClY conductance in resealed muscle fiber segments from patients with myotonic dystrophy. J Physiol 1990;425:391-405.
14. Mounsey JP, Puting Xu, John JE 3rd, et al. Modulation of skeletal muscle sodium channels by human myotonin protein kinase. J Clin Invest 1995;95:2379-2384.
15. Mounsey JP, Mistry DJ, Ai CW, et al. Skeletal muscle sodium channel gating in mice deficient in myotonic dystrophy protein kinase. Hum Mol Genet 2000;9(15):2313-2320.
16. Desnuelle C, Lombet A, Serratrice G, et al. Sodium channel and sodium pump in normal and pathological muscles from patients with myotonic muscular dystrophy and lower motor neuron impairment. J Clin Invest 1982;69:358-367.
17. Jacobs AE, Benders AA, Oosterhof A, et al. The calcium homeostasis and the membrane potential of cultured muscle cells from patients with myotonic dystrophy. Biochim Biophys Acta 1990;1096(1):14-19.
18. Kimura T, Nakamori M, Lueck JD, et al. Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1. Hum Mol Genet 2005;14:2189-2200.
19. Charlet BN, Savkur RS, Singh G, et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002;10(1):45-53.
20. Mankodi A, Takahashi MP, Jiang H, et al. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell 2002;10(1);35-44.
21. Renaud JF, Desnuelle C, Schmid-Antomarchi H, et al. Expression of apamin receptor in muscles of patients with myotonic muscular dystrophy. Nature 1986;319:678-680.
22. Kimura T, Takahashi MP, Okuda Y, et al. The expression of ion channel mRNAs in skeletal muscles from patients with myotonic muscular dystrophy. Neurosci Lett 2000;295:93-96.
23. Behrens MI, Jalil P, Serani A, et al. Possible role of apamin-sensitive K+ channels in myotonic dystrophy. Muscle Nerve 1994;17:1264-1270.
24. Terstappen GC, Pellacani A, Alderighi L, et al. The antidepressant fluoxetine blocks the human small conductance calcium-activated potassium channels SK1, SK2 and SK3. Neurosci Lett 2003;346:85-88.
25. Chisari C, D-Alessandro C, Manca ML, et al. Sarcolemmal excitability in myotonic dystrophy: assessment through surface EMG. Muscle Nerve 1998;21:543-546.
26. Chisari C, Simonella C, Rossi B. A surface EMG analysis of sarcolemma excitability alteration and myofiber degeneration in Steinert disease. Clin Neurophysiol 2001;112:1925-1930.
27. Merletti R, Lo Conte LR, Orizio C. Indices of muscle fatigue. J Electromyogr Kinesiol 1991;1(1):20-33.
28. Wheeler Thurman M. Myotonic Dystrophy: therapeutic strategies for the future. Neurotherapeutics 2008;5:592-600.
29. Trip J, Drost G, van Engelen BG, et al. Drug treatment for myotonia. Cochrane Database Syst Rev 2006;25(1):1-26.
30. Sugino M, Ohsawa N, Ito T, et al. A pilot study of dehydroepiandrosterone sulphate in myotonic dystrophy. Neurology 1998,51:586-589.
31. Garcia-Colunga J, Awad JN, Miledi R. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc Natl Acad Sci U S A 1997;94:2041-2044. (Pubitemid 27113958)
32. Kyu-Sang P, In-Deok K, Ki-Chang P, et al. Fluoxetine inhibits L-Type Ca2+ and transient outward K+ currents in rat ventricular myocytes. Yonsei Med J 1999;40(2):144-151.
33. Hara E, Reinach PS, Wen Q, et al. Fluoxetine inhibits K+ transport pathways (K+ efflux, Na+-K+-2Clj cotransport, and Na+ pump) underlying volume regulation in corneal endothelial cells. J Membr Biol 1999;171:75-85.
34. Maertens C,Wei L,Voets T, et al. Block by fluoxetine of volume-regulated anion channels. Br J Pharmacol 1999;126:508-514.
35. Traboulsie A, Chemin J, Kupfer E, et al. T-Type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. Mol Pharmacol 2006;69:1963-1968.